Holen Sie sich die Stockscreener-App
1.87
5.65%
0.10
Vorhandelsmarkt:
1.85
-0.02
-1.07%
Schlusskurs vom Vortag:
$1.77
Offen:
$1.77
24-Stunden-Volumen:
826.49K
Relative Volume:
0.58
Marktkapitalisierung:
$52.33M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-64.47M
KGV:
-0.3023
EPS:
-6.1852
Netto-Cashflow:
$-52.33M
1W Leistung:
+13.33%
1M Leistung:
+5.06%
6M Leistung:
-67.59%
1J Leistung:
-91.62%
1-Tages-Spanne:
$1.74
$1.88
1-Wochen-Bereich:
$1.59
$1.93
52-Wochen-Spanne:
$1.39
$23.37
Jasper Therapeutics Inc Stock (JSPR) Company Profile
Firmenname
Jasper Therapeutics Inc
Sektor
Branche
Telefon
(650) 549-1400
Adresse
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Vergleichen Sie JSPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
1.87 | 49.53M | 0 | -64.47M | -52.33M | -6.1852 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-08 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-07-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-07-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-07-07 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-02-13 | Eingeleitet | UBS | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-09-09 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-08 | Eingeleitet | BTIG Research | Buy |
| 2024-06-27 | Eingeleitet | Stifel | Buy |
| 2024-05-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-03 | Eingeleitet | Evercore ISI | Outperform |
| 2024-03-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-03-18 | Eingeleitet | TD Cowen | Outperform |
| 2023-08-11 | Eingeleitet | CapitalOne | Overweight |
| 2022-02-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-11-08 | Eingeleitet | Credit Suisse | Outperform |
| 2021-10-21 | Eingeleitet | William Blair | Outperform |
| 2021-10-20 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-10-13 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Jasper Therapeutics Inc Aktie (JSPR) Neueste Nachrichten
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Jasper Therapeutics, Inc. (JSPR) And Encourages Stockholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Jasper Therapeutics, Inc. (JSPR) And Encourages Stockholders to Connect - ACCESS Newswire
Penny Stocks To Watch NowDecember 2nd - MarketBeat
JSPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Jasper Therapeutics, Inc. (JSPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Jasper Therapeutics Reports Positive Phase 1b Study Results - MSN
Analysts Have Conflicting Sentiments on These Healthcare Companies: Jasper Therapeutics (JSPR) and Azitra Inc (AZTR) - The Globe and Mail
Jasper Therapeutics stock maintains Market Outperform rating at Citizens By Investing.com - Investing.com Canada
Jasper Therapeutics’ Briquilimab Program Shines Amid Financial Losses - StocksToTrade
Jasper Therapeutics, Inc. (JSPR) Stock: Surges as New Asthma Trial Data Shows Promising Results - parameter.io
Jasper Therapeutics’ Briquilimab: Stepping Up? - StocksToTrade
Can Jasper Therapeutics Deliver on New Studies? - timothysykes.com
$1 Stocks to Watch: JSPR, FTEL, BYND, TOON December 2025 More Inside - Barchart.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Jasper Therapeutics, Inc. (JSPR) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Jasper Therapeutics Anticipates Growth with Briquilimab Highlights - timothysykes.com
Why Is Jasper Therapeutics Stock Surging Tuesday?Jasper Therapeutics (NASDAQ:JSPR) - Benzinga
Can Jasper Therapeutics’ Progress Propel Its Stock? - timothysykes.com
JSPR Explodes on Briquilimab Asthma Breakthrough - RagingBull
Jasper Therapeutics Reports Positive Results For Briquilimab In Allergic Asthma Phase 1b Study - Nasdaq
Jasper Therapeutics Reports Positive Data from ETESIAN Study and BEACON Investigation - TradingView
Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation - The Manila Times
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in ... - Enidnews.com
Jasper Stock Jumps After Promising New Asthma Study Results - Sahm
Jasper Therapeutics To Host Webinar To Present BEACON And ETESIAN Study Results - Nasdaq
Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation - The Manila Times
Jasper Therapeutics to Host an Investor Webinar on December - GlobeNewswire
JSPR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
ROSEN, REGARDED INVESTOR COUNSEL, Encourages Jasper Therapeutics - The National Law Review
Jasper Therapeutics Inc. (JSPR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Driven Brands and Jasper Therapeutics on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Average Rating of “Hold” by Brokerages - Defense World
Companies Like Jasper Therapeutics (NASDAQ:JSPR) Could Be Quite Risky - Yahoo Finance
Jasper Therapeutics to Present at Upcoming Investor Conferences - Sahm
Jasper Therapeutics, Inc. (NASDAQ: JSPR) Investor Alert: Deadline in Lawsuit on November 18, 2025 - openPR.com
Jasper Therapeutics, Inc.Class A Common Stock (NQ: JSPR - Markets Financial Content
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Jasper Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit - NewMediaWire
DEADLINE ALERT for NX, JSPR, and KBR: The Law Offices of - GlobeNewswire
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
JSPR FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Announces that Jasper Therapeutics Investors Have Opportunity to Lead Class Action Lawsuit - Business Wire
Portnoy Law Firm Announces Class Action on Behalf of Jasper Therapeutics, Inc. Investors - GlobeNewswire
JSPR DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts Jasper Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit - ACCESS Newswire
Bragar Eagel & Squire, P.C. Reminds Stockholders of Jasper, - GlobeNewswire
Deadline Soon: Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - The AI Journal
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper - MarketScreener
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
JSPR DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds Jasper Therapeutics, Inc. Investors to Join the Class Action Lawsuit - ACCESS Newswire
JSPR DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages - GlobeNewswire
JSPR DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors ... - Bluefield Daily Telegraph
JSPR Stockholders Have Opportunity to Lead Jasper Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper - MarketScreener
Finanzdaten der Jasper Therapeutics Inc-Aktie (JSPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):